TATAA Biocenter Expands Offerings using AATI's Fragment AnalyzerTM to assess RNA quality in gene expression analysis
Published: Tuesday, January 1st, 2013
Tags: Customer Stories, Fragment Analyzer
TATAA Biocenter, Europe's leading provider of genomic services, is strengthening its quality assurance program by introducing RNA quality assessment using Advanced Analytical Technologies, Inc. (“AATI”) Fragment Analyzer into its company's Standard Operating Procedures (SOPs) for expression profiling. “As we are analysing more and more complex samples, including preserved materials such as formalin fixed and paraffin embedded tissues, soils and sewer samples, and other aggressive matrices, the quality of the extracted nucleic acids becomes critical for meaningful analysis. Much money can be saved by identifying problems at early stage and either discarding poor quality samples or replacing them. With the Fragment Analyzer we can do this in high throughput, at acceptable cost and with greatest confidence,” said Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.
Since the Fragment Analyzer product launch in early 2012, AATI has placed over 275 units worldwide and has quickly become the technology solution standard to which all others are measured within the rapidly expanding nucleic acids analysis industry.
“We couldn't be more pleased to have an organization with the creditability of TATAA Biocenter added to our customer list. The Fragment Analyzer was designed and built with end-users first in mind,” said Dr. Steven Lasky, founder and CEO of AATI. “When we speak with potential users of the Fragment Analyzer we hear the same problem, they are frustrated with the existing competitive solutions; lack of ability to scale with their throughput, lack of reproducible resolution and lack of ability to perform multiple assessments on a single machine. Our proprietary technology allows us to streamline sample processing steps, analyze PCR and NGS library DNA fragments, total and messenger RNA, genomic DNA and DNA mutation detection assays all under one foot print. Together these attributes facilitate an enhanced return on capital for our customers.”
About TATAA Biocenter
TATAA Biocenter is world's largest organizer of hands-on training in quantitative real-time PCR, Europe's leading provider of nucleic acid analysis services, and Sweden's most comprehensive distributor of products for nucleic acids analysis. TATAA Biocenter has the best equipped laboratories for qPCR based analysis in Europe, and provides full range of nucleic acid analysis services, including primer and probe design, assay validation, quality control, mRNA and protein expression profiling, SNP and rare mutation analyses, data mining, pathway analysis, and kit and instrument evaluation to pharmaceutical and biotech companies. TATAA offers a seamless workflow, with all the instrumentation necessary for performing high quality experiments and for optimal sample handling, meeting the specific requirements for compliance with ISO17025 standard. TATAA core facility laboratories are also available for academic researchers. Founded in 2001, TATAA has permanent facility in Gothenburg, Sweden, and Prague, Czech Republic. For more information about TATAA Biocenter, see www.tataa.com or contact us on firstname.lastname@example.org
About Advanced Analytical Technologies, Inc.
AATI provides innovative solutions to improve processes and accelerate research results through quality data output within the pharmaceutical, life science, biofuels and biotechnology markets. AATI's product portfolio includes instruments for the parallel analysis of biomolecules, nucleic acids and proteins by capillary electrophoresis as well as a full line of certified reagents and off the shelf kits to meet customer needs. Founded in 1997, AATI has facilities in Ames, Iowa, USA and Heidelberg, Germany as well as a network of highly qualified distributors throughout the world. For more information visit the company's website at https://www.aati-us.com or contact us at email@example.com.
Access TATAA Sweden BioCenter 2013 here.